Survival rates in pregnancies complicated by twin-to-twin transfusion syndrome undergoing laser therapy: a systematic review and meta-analysis: Survival rates in twin-to-twin transfusion syndrome.
Francesco D'Antonio, Delia Marinceu, Nashwa Eltaweel, Smriti Prasad, Asma Khalil
{"title":"Survival rates in pregnancies complicated by twin-to-twin transfusion syndrome undergoing laser therapy: a systematic review and meta-analysis: Survival rates in twin-to-twin transfusion syndrome.","authors":"Francesco D'Antonio, Delia Marinceu, Nashwa Eltaweel, Smriti Prasad, Asma Khalil","doi":"10.1016/j.ajogmf.2024.101503","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Twin-to-twin transfusion syndrome (TTTS) is associated with excess perinatal mortality and morbidity. Even though Quintero staging is commonly used to assess its severity, the limitations of its prognostic value have been highlighted by researchers over the years. Recent literature indicates that fetal survival, whether for both twins or at least one, following fetoscopic laser photocoagulation of the placental anastomoses is similar in TTTS Quintero stages I and II (combined) and III and IV (combined). In this context we perform a systematic review and meta-analysis of the published literature to elucidate the survival rate of twins according to the stage of TTTS and to compare the survival rates in pregnancies complicated by stage I and II (combined) vs those with stages III and IV (combined).</p><p><strong>Data sources: </strong>Medline, Embase and Cochrane databases were searched.</p><p><strong>Study eligibility criteria: </strong>The inclusion criteria were studies reporting the outcome of MCDA twin pregnancies with TTTS undergoing laser therapy according to the Quintero stage of the disease. The primary outcome was double survival at birth. The secondary outcomes were no survival, and survival of at least one twin. All the explored outcomes were reported according to the Quintero staging system. Furthermore, we aimed to compare all the observed outcomes in pregnancies complicated by TTTS affected by stage I and II vs those with stages III and IV.</p><p><strong>Study appraisal and synthesis methods: </strong>Random-effect meta-analyses were used to combine data, and the results reported as pooled proportions or odd ratios (OR) with their 95% confidence intervals (CI).</p><p><strong>Results: </strong>26 studies were included. Survival of both fetuses was observed in 72.9% (95% CI 68.2-77.3) of pregnancies complicated by stage I, 67.9% (95% CI 62.3-73.3) with stage II, 48.1% (95% CI 42.5-53.8) with stage III, and 53.4% (95% CI 42.5-64.3) with stage IV TTTS (Table 3). At least one survivor was reported in 89.4% (95% CI 86.9-91.9) of cases with stage I, 87.1% (95% CI 82.9-90.7) with stage II, 77.3% (95% CI 71.7-82.5) with stage III, and 80.1% (95% CI 69.4-89.0) with stage 4. The corresponding figures for no survivors were 10.7% (95% CI 7.7-14.0), 11.4% (95% CI 7.8-15.6), 20.4% (95% CI 15.6-25.8), and 16.7% (95% CI 8.3-27.2), respectively. When comparing the different outcomes according to the different TTTS stages, there was no significant difference in the incidence of double survival (p=0.933), at least one survivor (p=0.688), and no survivors (p=0.866) between stages I and II TTTS. There was also no significant difference in the incidence of double survival (p=0.201), at least one survivor (p=0.380), and no survivors (p=0.947) between stages III and IV. Conversely, when comparing the outcome of pregnancies with stage I/II (combined) vs stages III/IV (combined), the incidence of double survival was significantly higher in pregnancies with stages I/II (OR 2.19; 95% CI 1.9-2.6, p<0.001) (Table 5). Likewise, the incidence of at least one survivor was significantly higher (OR 1.85, 95% CI 1.5-2.6, p<0.001) while that of no survivor (OR 0.56, 95% CI 0.4-0.7, p<0.001) significantly lower in pregnancies with stages I/II compared to III/IV.</p><p><strong>Conclusion: </strong>Perinatal survival of MCDA twin pregnancies complicated by TTTS and treated with fetoscopic laser coagulation of placental anastomoses is not significantly different between stages I and II, or between stages III and IV, apart from a higher chance of one survivor in stage III compared to stage IV. The findings from this systematic review will be useful in individualised risk assessment of twin pregnancies complicated by TTTS and tailored counselling of the parents. It also highlights the need for studies aimed at better characterizing the prenatal risk factors for mortality in pregnancies complicated by TTTS.</p><p><strong>Condensation: </strong>Perinatal survival of MCDA twin pregnancies complicated by TTTS and treated with fetoscopic laser coagulation of placental anastomoses is not significantly different between stages I and II, or between stages III and IV.</p>","PeriodicalId":36186,"journal":{"name":"American Journal of Obstetrics & Gynecology Mfm","volume":" ","pages":"101503"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Obstetrics & Gynecology Mfm","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajogmf.2024.101503","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Twin-to-twin transfusion syndrome (TTTS) is associated with excess perinatal mortality and morbidity. Even though Quintero staging is commonly used to assess its severity, the limitations of its prognostic value have been highlighted by researchers over the years. Recent literature indicates that fetal survival, whether for both twins or at least one, following fetoscopic laser photocoagulation of the placental anastomoses is similar in TTTS Quintero stages I and II (combined) and III and IV (combined). In this context we perform a systematic review and meta-analysis of the published literature to elucidate the survival rate of twins according to the stage of TTTS and to compare the survival rates in pregnancies complicated by stage I and II (combined) vs those with stages III and IV (combined).
Data sources: Medline, Embase and Cochrane databases were searched.
Study eligibility criteria: The inclusion criteria were studies reporting the outcome of MCDA twin pregnancies with TTTS undergoing laser therapy according to the Quintero stage of the disease. The primary outcome was double survival at birth. The secondary outcomes were no survival, and survival of at least one twin. All the explored outcomes were reported according to the Quintero staging system. Furthermore, we aimed to compare all the observed outcomes in pregnancies complicated by TTTS affected by stage I and II vs those with stages III and IV.
Study appraisal and synthesis methods: Random-effect meta-analyses were used to combine data, and the results reported as pooled proportions or odd ratios (OR) with their 95% confidence intervals (CI).
Results: 26 studies were included. Survival of both fetuses was observed in 72.9% (95% CI 68.2-77.3) of pregnancies complicated by stage I, 67.9% (95% CI 62.3-73.3) with stage II, 48.1% (95% CI 42.5-53.8) with stage III, and 53.4% (95% CI 42.5-64.3) with stage IV TTTS (Table 3). At least one survivor was reported in 89.4% (95% CI 86.9-91.9) of cases with stage I, 87.1% (95% CI 82.9-90.7) with stage II, 77.3% (95% CI 71.7-82.5) with stage III, and 80.1% (95% CI 69.4-89.0) with stage 4. The corresponding figures for no survivors were 10.7% (95% CI 7.7-14.0), 11.4% (95% CI 7.8-15.6), 20.4% (95% CI 15.6-25.8), and 16.7% (95% CI 8.3-27.2), respectively. When comparing the different outcomes according to the different TTTS stages, there was no significant difference in the incidence of double survival (p=0.933), at least one survivor (p=0.688), and no survivors (p=0.866) between stages I and II TTTS. There was also no significant difference in the incidence of double survival (p=0.201), at least one survivor (p=0.380), and no survivors (p=0.947) between stages III and IV. Conversely, when comparing the outcome of pregnancies with stage I/II (combined) vs stages III/IV (combined), the incidence of double survival was significantly higher in pregnancies with stages I/II (OR 2.19; 95% CI 1.9-2.6, p<0.001) (Table 5). Likewise, the incidence of at least one survivor was significantly higher (OR 1.85, 95% CI 1.5-2.6, p<0.001) while that of no survivor (OR 0.56, 95% CI 0.4-0.7, p<0.001) significantly lower in pregnancies with stages I/II compared to III/IV.
Conclusion: Perinatal survival of MCDA twin pregnancies complicated by TTTS and treated with fetoscopic laser coagulation of placental anastomoses is not significantly different between stages I and II, or between stages III and IV, apart from a higher chance of one survivor in stage III compared to stage IV. The findings from this systematic review will be useful in individualised risk assessment of twin pregnancies complicated by TTTS and tailored counselling of the parents. It also highlights the need for studies aimed at better characterizing the prenatal risk factors for mortality in pregnancies complicated by TTTS.
Condensation: Perinatal survival of MCDA twin pregnancies complicated by TTTS and treated with fetoscopic laser coagulation of placental anastomoses is not significantly different between stages I and II, or between stages III and IV.
目的:双胎输血综合征(TTTS)与围产期死亡率和发病率过高有关。尽管昆特罗分期常用于评估其严重程度,但多年来研究人员一直在强调其预后价值的局限性。最近的文献表明,胎儿镜激光光凝胎盘吻合口后,无论是双胎还是至少一胎,TTTS 昆特罗分期 I、II(合并)和 III、IV(合并)的胎儿存活率相似。在此背景下,我们对已发表的文献进行了系统回顾和荟萃分析,以根据 TTTS 的分期阐明双胞胎的存活率,并比较 I 期和 II 期(合并)与 III 期和 IV 期(合并)并发症妊娠的存活率:研究资格标准:纳入标准为根据昆特罗疾病分期对接受激光治疗的 MCDA 双胎 TTTS 结果进行报告的研究。主要结果是出生时双胎存活。次要结果是无存活和至少有一个双胞胎存活。所有探讨的结果均根据昆特罗分期系统进行报告。此外,我们还旨在比较I期和II期TTTS并发妊娠与III期和IV期TTTS并发妊娠的所有观察结果:结果:共纳入 26 项研究。在 I 期并发 TTTS 的孕妇中,72.9%(95% CI 68.2-77.3)、II 期 67.9%(95% CI 62.3-73.3)、III 期 48.1%(95% CI 42.5-53.8)、IV 期 53.4%(95% CI 42.5-64.3)的胎儿存活(表 3)。89.4% (95% CI 86.9-91.9)的 I 期病例、87.1% (95% CI 82.9-90.7)的 II 期病例、77.3% (95% CI 71.7-82.5)的 III 期病例和 80.1% (95% CI 69.4-89.0)的 4 期病例至少有一名幸存者。无幸存者的相应数字分别为10.7%(95% CI 7.7-14.0)、11.4%(95% CI 7.8-15.6)、20.4%(95% CI 15.6-25.8)和16.7%(95% CI 8.3-27.2)。在比较不同 TTTS 分期的不同结果时,I 期和 II 期 TTTS 的双胎存活率(P=0.933)、至少一胎存活率(P=0.688)和无一胎存活率(P=0.866)均无显著差异。在 III 期和 IV 期之间,双胎存活率(p=0.201)、至少一名存活者(p=0.380)和无存活者(p=0.947)的发生率也无明显差异。相反,在比较Ⅰ/Ⅱ期(合并)与Ⅲ/Ⅳ期(合并)妊娠的结局时,Ⅰ/Ⅱ期妊娠的双胎存活率明显更高(OR 2.19;95% CI 1.9-2.6,p):并发 TTTS 并接受胎儿镜激光凝固胎盘吻合术治疗的 MCDA 双胎妊娠的围产期存活率在 I 期和 II 期、III 期和 IV 期之间没有明显差异,只是 III 期比 IV 期有更高的单胎存活率。本系统综述的研究结果将有助于对并发 TTTS 的双胎妊娠进行个体化风险评估,并为父母提供量身定制的咨询服务。该研究还强调,有必要开展研究,以更好地确定TTTS并发症孕妇的产前死亡风险因素:TTTS并发的MCDA双胎妊娠在接受胎儿镜激光凝固胎盘吻合术治疗后,其围产期存活率在I期和II期、III期和IV期之间没有显著差异。
期刊介绍:
The American Journal of Obstetrics and Gynecology (AJOG) is a highly esteemed publication with two companion titles. One of these is the American Journal of Obstetrics and Gynecology Maternal-Fetal Medicine (AJOG MFM), which is dedicated to the latest research in the field of maternal-fetal medicine, specifically concerning high-risk pregnancies. The journal encompasses a wide range of topics, including:
Maternal Complications: It addresses significant studies that have the potential to change clinical practice regarding complications faced by pregnant women.
Fetal Complications: The journal covers prenatal diagnosis, ultrasound, and genetic issues related to the fetus, providing insights into the management and care of fetal health.
Prenatal Care: It discusses the best practices in prenatal care to ensure the health and well-being of both the mother and the unborn child.
Intrapartum Care: It provides guidance on the care provided during the childbirth process, which is critical for the safety of both mother and baby.
Postpartum Issues: The journal also tackles issues that arise after childbirth, focusing on the postpartum period and its implications for maternal health. AJOG MFM serves as a reliable forum for peer-reviewed research, with a preference for randomized trials and meta-analyses. The goal is to equip researchers and clinicians with the most current information and evidence-based strategies to effectively manage high-risk pregnancies and to provide the best possible care for mothers and their unborn children.